Pharma Penny Stock Under Rs 50 In Green After Signing MoU with Respilon Group s.r.o
From Rs 34.51 per share (52-week low) to Rs 43.93 per share, the stock is up by 27.3 per cent.
Today, shares of Sigachi Industries Ltd gained 2.6 per cent to Rs 43.93 per share from its previous closing of Rs 42.82 per share. The company has a market cap of over Rs 1,400 crore and has delivered good profit growth of 25 per cent CAGR over the last 5 years.
Sigachi Industries Limited, through its wholly-owned subsidiary Sigachi MENA FZCO, has forged a strategic partnership with Respilon Group s.r.o., a Czech Republic-based nanofiber R&D company, by signing a Memorandum of Understanding as formalised by Mr. Lijo Chacko and Mr. Roman Zima; this collaboration aims to revolutionize patient experience and therapeutic outcomes by leveraging Respilon’s innovative NUENEX® nanofiber technology to develop, manufacture, and commercialize non-invasive, precision drug delivery solutions, with an initial focus on Invisible Patch and Powder-based pharmaceutical delivery formats, including the development of commercialization strategies for relevant APIs and formulations utilizing nanofiber encapsulation technology.
Commenting on this development, Amit Raj Sinha, Managing Director and CEO of Sigachi Industries Limited, stated, “Partnering with Respilon aligns perfectly with our vision to deliver next-generation pharmaceutical solutions that improve therapeutic outcomes and elevate the patient experience. We are excited about the possibilities NUENEX® technology offers to revolutionise drug delivery systems globally.”
Commenting on this development, Mr. Roman Zima, Chief Business Officer of Respilon Group s.r.o., stated, “We are delighted to partner with Sigachi, whose deep industry expertise and global reach will accelerate the deployment of NUENEX® across pharmaceutical markets. Together, we aspire to redefine drug delivery with safer, more effective, and sustainable solutions for patients worldwide.”
DSIJ’s 'Tiny Treasure' service recommends researched Small-Cap stocks with Inherent Growth Potential. If this interests you, do download the service details here.
About the Company
Sigachi Industries Limited, a publicly traded pharmaceutical company listed on NSE and BSE, is a global leader in providing high-quality excipients, vitamin-mineral nutrient blends, APIs, and O&M services. With over 35 years of industry expertise, Sigachi has built a strong reputation as a trusted partner for pharmaceutical and nutraceutical companies worldwide. They specialise in innovative solutions for food stability, fortification, and nutrition, offering tailored blends of vitamins, minerals, and other ingredients to meet the evolving needs of consumers. By utilising advanced technologies like blending, encapsulation, and spray drying, Sigachi empowers food manufacturers to create products with superior taste, quality, and nutritional value, contributing to a healthier and happier world.
The company announced positive Quarterly Results (Q3FY25) and nine-month results (9MFY24). According to quarterly results, revenue increased by 26 per cent to Rs 139.42 crore, EBITDA increased by 45 per cent to Rs 35.19 crore and consolidated net profit increased by 33 per cent to Rs 21.35 crore in Q3FY25 compared to Q3FY24. In its nine-month results, revenue increased by 22 per cent to Rs 360.03 crore, EBITDA increased by 39 per cent to Rs 89.75 crore and consolidated PAT increased by 33 per cent to Rs 56.29 crore in 9MFY25 compared to 9MFY24.
From Rs 34.51 per share (52-week low) to Rs 43.93 per share, the stock is up by 27.3 per cent. Investors should keep an eye on this small-cap pharma stock.
Disclaimer: The article is for informational purposes only and not investment advice.